跳至主要内容
临床试验/NCT00588588
NCT00588588撤回3 期

Bronchoscopy Versus Clinical Pulmonary Infection Score Guided Approach in Suspected Ventilator-Associated Pneumonia (VAP): Randomized Clinical Trial

Mayo Clinic0 个研究点开始时间: 2007年1月最近更新:
适应症

试验速览

阶段
3 期
状态
撤回
发起方
Mayo Clinic
主要终点
14-day antibiotic free days

研究概览

简要总结

The reported incidence of ventilator associated pneumonia (VAP) is 10 to 15 per 1,000 ventilator days. VAP leads to an excess cost exceeding $40,000 per patient and is associated with a crude mortality rate as high as 76%. The clinical criteria for the diagnosis of VAP have low specificity and may lead to unnecessary antibiotic use. The Clinical Pulmonary Infection Score (CPIS) and bronchoscopic approaches lower unnecessary antimicrobial use, antimicrobial resistance, and superinfection compared to the traditional clinical criteria.

Based on the available evidence and local microbiology data, we have developed a VAP management protocol guided by CPIS or bronchoalveolar lavage (BAL) in adults with suspected VAP. These two approaches have not been compared against each other. Although the diagnostic studies in the CPIS guided approach are inexpensive and easily available, BAL has the potential to minimize the unnecessary use of antibiotics and reduce the development of drug resistant pathogens.

In this study, we propose to test the hypothesis that BAL leads to a reduction in antibiotic use compared to CPIS in patients with suspected VAP. The study design will be a randomized, clinical trial comparing CPIS versus BAL. The primary outcome measure will be antibiotic utilization. The secondary outcome measures will be mortality, morbidity, development of resistant pathogens and superinfection and infection related financial burden.

Completion of this trial will help us identify the best approach to avoid unnecessary antibiotic utilization and minimize the development of resistant pathogens (with their associated morbidity and mortality) in critically ill patients.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
None

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Age >= 18 years
  • Endotracheal intubation
  • Suspected VAP with:
  • New or progressive pulmonary infiltrates plus two of the following (In patients with pre-existing ALI or ARDS, physicians' suspicion of VAP with two of the listed criteria will be used.): Temperature > 38 C or < 36 C, WBC > 12,000/mL or < 4,000/mL, purulent endotracheal secretions.
  • Patient or legally authorized representative is able to sign Informed Consent

排除标准

  • Prison inmates
  • Immunocompromised patients
  • Participation in another trial conflicting with the design of the current trial
  • Previous history of VAP during the same hospitalization
  • Previous participation in the current study
  • Concomitant non-pulmonary infection diagnosed within 3 days preceding the suspected VAP
  • Patient's primary care provider does not want subject to be enrolled in the study
  • Contraindications for bronchoscopy

结局指标

主要结局

14-day antibiotic free days

时间窗: Day 14 of enrolment

次要结局

  • Daily organ failure score(14 days)
  • Length of hospital stay(Hospital stay)
  • Mortality(28 days)

研究者

发起方
Mayo Clinic
申办方类型
Other

相似试验